Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 18/20 | 0.46 |
| ▸ | BRD2 | P25440 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240362 | 0.82 | ACVR1 (0.47) | BRD4 | |
| SCHEMBL4242137 | 0.80 | PRMT5 (0.50) | BRD4CREBBP | |
| SCHEMBL4247370 | 0.77 | ALK (0.37) | — | |
| SCHEMBL4509185 | 0.74 | CHEK1 (0.44) | JAK2 | |
| SCHEMBL4496917 | 0.74 | CHEK1 (0.47) | — | |
| SCHEMBL4508970 | 0.74 | CHEK1 (0.51) | — | |
| SCHEMBL4508605 | 0.74 | PIM1 (0.39) | — | |
| SCHEMBL4517652 | 0.73 | LTK (0.39) | — | |
| SCHEMBL4500850 | 0.73 | CHEK1 (0.48) | PGR | |
| SCHEMBL17698802 | 0.72 | BRD4 (0.42) | JAK2BRD4BRD2CREBBPNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501435-B2 | Inhibitors of checkpoint kinases | MERCK & CO., INC. (US) | 2009-03-10 | — | — | US | disclosed |
| WO-2007127138-A1 | TRIAZOLOQUINAZOLINONE DERIVATIVES AS INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
| US-20070254879-A1 | Inhibitors of checkpoint kinases | MERCK SHARP & DOHME CORP. | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254879-A1 | Inhibitors of checkpoint kinases | CHEK1, CHEK2, PLK1 | JAK2 979/4885BRD4 304/4885BRD2 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.